RT Journal Article
SR Electronic
T1 VEGF in Patients with Non-small Cell Lung Cancer during Combination Chemotherapy of Carboplatin and Paclitaxel
JF Anticancer Research
JO Anticancer Res
FD International Institute of Anticancer Research
SP 2635
OP 2639
VO 29
IS 7
A1 SHINGYOJI, MASATO
A1 ANDO, SOICHIRO
A1 NISHIMURA, HIROKI
A1 NAKAJIMA, TAKAHIRO
A1 ISHIKAWA, AKI
A1 ITAKURA, MEIJI
A1 IIZASA, TOSHIHIKO
A1 KIMURA, HIDEKI
YR 2009
UL http://ar.iiarjournals.org/content/29/7/2635.abstract
AB Background: Vascular endothelial growth factor (VEGF) is a potent angiogenic factor related to tumor growth and metastasis. However, little is known about the clinical significance of circulating VEGF in cancer patients. Patients and Methods: Eighteen patients with non-small cell lung cancer received chemotherapy using carboplatin and paclitaxel. Plasma levels of VEGF were analyzed at baseline and after 2 cycles of chemotherapy. Results: Partial remission was observed in 3 patients (16.7%), stable disease in 10 patients (55.6%) and progressive disease in 5 patients (27.8%). Patients with partial remission or stable disease had significantly lower levels of plasma VEGF than did patients with progressive disease, both at baseline (p=0.0341) and after 2 cycles of chemotherapy (p=0.0265). There were no significant changes of plasma VEGF during chemotherapy. Conclusion: Pretreatment plasma levels of VEGF are a useful marker for predicting disease control by chemotherapy.